Physician profile
Daniel Man
NPI 1932245917
$1,718.33
in general payments reported to CMS, 2019-2025
12 companies · $62.89 in 2025
The $62.89 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $204 · 2021: $223 · 2022: $13.00 · 2023: $93.76 · 2024: $19.05 · 2025: $62.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $745.97 | 2019-2021 | |
| Merz North America, INC. | $347.74 | 2019 | |
| Mentor Worldwide LLC | $264.89 | 2019-2021 | |
| Dilon Technologies, INC. | $93.76 | 2023 | Hemoblast Bellows |
| Abbvie INC. | $59.61 | 2024-2025 | |
| Allergan, INC. | $54.66 | 2019-2021 | |
| Medtronic, INC. | $41.67 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $30.61 | 2019-2020 | |
| Sientra, INC. | $24.32 | 2020 | |
| Solta Medical, A Division of Bausch Health US, LLC | $22.33 | 2025 | |
| Smith+Nephew, INC. | $18.23 | 2020 | |
| Convatec INC. | $14.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Man listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.